Astrana Health, Inc. (ASTH) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Astrana Health, Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company operating through three segments: Care Partners, Care Delivery, and Care Enablement. As of March 31, 2025, the Company managed over 1.0 million patients across 20 independent risk-bearing organizations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $620.4 million | $404.4 million |
| Net Income (GAAP) | $6.2 million | $16.9 million |
| Net Income Attributable to Astrana | $6.7 million | $14.8 million |
| Adjusted EBITDA | $36.4 million | $42.2 million |
| Operating Cash Flow | $16.6 million | $6.0 million |
| Cash & Equivalents | $258.5 million | $334.8 million |
| Total Debt (Gross) | $421.9 million | $438.1 million |
| Working Capital | $252.0 million | $272.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 53% ($216.0 million) year-over-year, driven primarily by a 60% increase in capitation revenue due to recent acquisitions and enrollee transitions to full risk.
- Profitability Decline: Net income attributable to Astrana decreased by 55% ($8.1 million). Operating income fell 32% to $20.6 million, impacted by higher medical utilization costs and increased general and administrative expenses.
- Segment Performance:
- Care Partners: Revenue up 57% to $601.0 million; Operating income up 2% to $44.2 million.
- Care Delivery: Revenue up 9% to $33.4 million; Operating loss widened to $3.1 million (from $0.2 million loss) due to costs associated with new clinic locations.
- Care Enablement: Revenue up 19% to $39.6 million; Operating income remained flat at $3.5 million.
- Debt Restructuring: In February 2025, the Company entered a new credit agreement providing a $300 million revolver, $250 million term loan, and a $745 million delayed draw term loan. This refinanced existing debt and incurred $5.0 million in expensed debt issuance costs.
Guidance, Outlook, and Risks
- Acquisition Update: Astrana received HSR approval for its pending acquisition of Prospect Health, expected to close in summer 2025. The delayed draw term loan is designated to fund this transaction.
- Liquidity: Management believes it has sufficient liquidity to fund operations for at least the next 12 months. Cash decreased by $30.0 million during the quarter, primarily due to debt refinancing costs and working capital changes.
- Risks:
- Regulatory: Complex laws governing Medicare and Medicaid programs subject the Company to potential fines, penalties, or exclusion.
- Contingent Consideration: Significant liabilities exist for earn-outs related to recent acquisitions (e.g., CHS, CFC, ADSC), totaling approximately $30.0 million in fair value as of March 31, 2025.
- Interest Rate: Floating-rate debt exposes the Company to interest rate variability, partially mitigated by an interest rate collar (cap 5.0%, floor 2.34%).
Investor Verification Checklist
- Prospect Health Acquisition: Verify the closing timeline and integration costs for the pending Prospect Health acquisition.
- Medical Utilization Trends: Monitor the impact of higher utilization rates on the Care Partners segment's margins, which offset revenue growth.
- Debt Covenants: Review compliance with the new leverage ratio (max 5.0x) and interest coverage ratio (min 2.5x) under the Second Amended and Restated Credit Agreement.
- Contingent Liabilities: Assess the probability of meeting earn-out metrics for recent acquisitions (CHS, CFC, ADSC) which could trigger significant cash outflows.
- Cash Flow Timing: Note the 18-month lag in risk pool settlements, which impacts short-term working capital and receivables.